Jazz Pharmaceuticals plc (JAZZ)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Ireland
Exchange: NASDAQ
Market cap: $15.63B
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Latest financial period: June 30, 2026
Filed with the SEC: August 3, 2026
Estimated earnings date: November 4, 2026
Profit #947 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 6.8% | 2.3% | 0.2% | -0.5% |
Growth #440 of 1484 companies
Payout #1117 of 1484 companies
Safety #569 of 1484 companies
Price #207 of 1484 companies
